BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 2:25:00 PM | Browse: 640 | Download: 358
Publication Name World Journal of Hematology
Manuscript ID 1878
Country of Manuscript Source Netherlands
Received
2013-01-11 08:57
Peer-Review Started
2013-01-11 14:25
To Make the First Decision
2013-02-26 14:48
Return for Revision
2013-04-10 08:51
Revised
Second Decision
2013-06-18 09:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-06-18 23:58
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-07-15 15:37
Publish the Manuscript Online
2013-07-25 22:33
ISSN 2218-6204 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Hematology
Manuscript Type Review
Article Title PVSG and WHO vs European Clinical, Molecular and Pathological Criteria for prefibrotic myeloproliferative neoplasms
Manuscript Source Invited Manuscript
All Author List Jan Jacques Michiels, Zwi Berneman, Wilfried Schroyens, King H Lam and Hendrik De Raeve
Funding Agency and Grant Number
Corresponding author Jan Jacques Michiels, MD, PhD, Senior Internist, European Working Group on Myeloproliferative Neoplasms, Goodheart Institute, Erasmus Tower, Veenmos 13, 3069 AT, Rotterdam, The Netherlands. goodheartcenter@upcmail.nl
Keywords Myeloproliferative neoplasms; Essential thrombocythemia; Prodromal polycythemia vera; Polycythemia vera; Myelofibrosis; JAK2V617F mutation; JAK2 wild type myeloproliferative neoplasm; Bone marrow pathology
Core Tip The integrated World Health Organization (WHO) and European Clinical, Molecular and Pathological classification of the myeloproliferative neoplasms include JAK2V617F mutated normocellular essential thrombocythemia (WHO-ET), prodromal polycythemia vera (PV), classical PV, and hypercellular ET due to megakaryocytic, granulocytic myeloproliferation. Evolution of prodromal PV into overt PV is common. JAK2/MPL wild hypercellular ET associated with prefibrotic primary megakaryocytic and granulocytic myeloproliferation is characterized by densely clustered immature dysmorphic megakaryocytes with bulky (bulbous) hyperchromatic nuclei, which are never seen in JAK2V617F mutated ET and PV, and also not in JAK2 wild type normocellular ET (WHO-ET) carrying the MPL515 mutation.
Publish Date 2013-07-25 22:33
Citation Michiels JJ, Berneman Z, Schroyens W, Lam KH, De Raeve H. PVSG and WHO vs ECMP criteria for prefibrotic myeloproliferative neoplasms. World J Hematol 2013; 2(3): 71-88
Url http://www.wjgnet.com/2218-6204/full/v2/i3/71.htm
DOI http://dx.doi.org/10.5315/wjh.v2.i3.71
Full Article (PDF) WJH-2-71.pdf
Manuscript File 1878-Review.docx
Answering Reviewers 1878-Answering reviewers.doc
Copyright License Agreement 1878-Copyright assignment.pdf
Peer-review Report 1878-Peer review(s).pdf
Scientific Editor Work List 1878-Scientific editor work list.doc